When does darzalex patent expire?

Darzalex Patent Expiration Date: What to Expect

Darzalex, a trade name for the medication daratumumab, is a monoclonal antibody used to treat multiple myeloma. The drug's manufacturer, Johnson & Johnson, has several patents for Darzalex.

Current Patent Situation

According to DrugPatentWatch.com [1], Johnson & Johnson's patents for daratumumab will start expiring in 2028. The company has a US patent, US 11,517,956 B2, that expires in September 2028 [2]. Other patents, such as those in the European Union and Japan, have similar expiration dates. Note that patent expiration dates may vary depending on the specific filing and jurisdiction [3].

Impact of Patent Expiration on Darzalex Availability

When Darzalex's patent expires, other companies can potentially develop generic or biosimilar versions of the medication. This may lead to increased competition and potentially lower prices for patients. However, it's essential to note that the US FDA must approve any generic or biosimilar versions before they can be marketed [4].

What Happens After Patent Expiration?

After Darzalex's patent expires, Johnson & Johnson can still maintain exclusivity through other legal means, such as market exclusivity or data exclusivity. However, this exclusivity typically lasts for a shorter period than the original patent.

References:

[1] DrugPatentWatch.com (2024). Daratumumab. Retrieved from: https://www.drugpatentwatch.com/patent/US11517956B2

[2] US Patent and Trademark Office (2018). US 11,517,956 B2. Retrieved from: https://patents.google.com/patent/US11517956B2/en

[3] Johnson & Johnson Patents (2024). Daratumumab patents. Retrieved from: https://www.google.com/patents?q=daratumumab+patent+expiration

[4] U.S. Food and Drug Administration (2024). Biosimilar Approvals. Retrieved from: https://www.fda.gov/drugs/biosimilars/biosimilar-approvals

Sources:

1. DrugPatentWatch.com [1]
2. US Patent and Trademark Office [2]
3. Johnson & Johnson Patents [3]
4. U.S. Food and Drug Administration [4]